Eagle Pharmaceuticals and USAMRICD Signs an Agreement for Ryanodex (dantrolene sodium)

 Shots:

• United States Army Medical Research Institute of Chemical Defense (USAMRICD) and Eagle collaborates for evaluating the neuroprotective effects of Ryanodex
• Eagle will bear the research study cost and will be conducted under a Cooperative Research and Development Agreement (CRADA), allowing government laboratories to partner with private industries or academia for R&D projects
• If approved post research study, Ryanodex will be a novel neuroprotective treatment for amelioration of neurological damage due to nerve agent exposure

Click here to read full press release/ article | Ref: Eagle Pharmaceuticals | Image: Business wire